Management
The Thor Medical team is dedicated to establish a profitable production of alpha-emitters for Radionuclide Therapy.
Jasper Kurth joined Thor Medical ASA as CEO in August 2024. Previously, he served as General Manager for Bayer's Radiology division in the Nordic markets, based out of Stockholm, Sweden. Throughout his career at Bayer, Jasper has gained extensive experience in both strategy and operations across various divisions, including a tenure at Bayer's corporate headquarters in Leverkusen, Germany. Jasper holds a master's-equivalent degree in Business Information Management. He is married and has two young children. Number of shares: 0 Number of options: 3 600 000
Jasper Kurth
CEO
Brede Ellingsæter joined Thor Medical as CFO in July 2023. Prior to Thor Medical he was the CFO in Scatec Innovation. Ellingsæter has also had an extensive career in Elkem ASA, where he held several various senior positions including CFO of Carbon Solutions division during his 8 years with the company. Ellingsæter holds a Master of Business and Economics from Norwegian School of Economics (NHH). Number of shares: 0 Number of options: 3 100 000
Brede Ellingsæter
CFOO
Dr. Alf Bjørseth has a long track record of establishing new companies based on proprietary developed technologies, primarily within the areas of renewable energy and advanced materials. His efforts have resulted in a number of new businesses like REC, NorSun, Scatec Solar ASA, Norsk Titanium and REEtec AS. He will be best know for having founded ScanWafer in 1994, followed by other companies within the solar industry, all merged into Renewable Energy Corporation in 2000 where he served as President and CEO until the fall of 2005. Alf Bjørseth holds a Doctor Phil. in physical chemistry from the University of Oslo. He started his career as a researcher and were Corporate Director of Research at Norsk Hydro and Director of Technology for Elkem.
Alf Bjørseth
EVP Business Development
Hassfjell holds an M.Sc. 1992 and D.Sc. 1997 in nuclear chemistry from University of Oslo (UiO). He has more than 30 years’ experience in nuclear and radiochemistry scientific research with experience of all radioactivity levels (A, B, C-lab) with several alpha- and beta-emitters from radionuclide production to development of radiopharmaceuticals and preclinical testing. Hassfjell has been scientist and project leader at IFE and Director of generator development for ARTBIO before joining Thor Medical. His career also include Post Doc at UiO, NIH and University of Chicago (USA) developing production methods for alpha emitters and microdosimetric methodology. Number of shares: 0; Number of options: 2 700 000
Sindre Hassfjell
CTO
Astrid Liland joined Thor Medical on 1 January 2024 as VP EHS. Before joining Thor Medical, she was Director of nuclear emergency and response at the Norwegian radiation and nuclear safety authority (DSA). Liland has 25 years’ experience in radiation research, environmental radioactivity, radioactive contamination and consequences for man and the environment. She has been active in the nuclear scientific research community through many national, Nordic, European and international research projects. Liland holds a Master of Science in nuclear chemistry from the University of Oslo (UiO). Number of shares: 0 Number of options: 2 100 000
Astrid Liland
EVP HSEQ
Board of Directors
Mr. Andersen is the CEO of Scatec Innovation AS. Previously, he was the Chief Operating Officer of the REC Group, where he held several top management positions during his 12 years with the company. Prior to REC, he worked in Borregaard Industrier. Mr. Andersen is the Chair of Scatec ASA, Norsk Titanium AS, NorSun AS, as well as a number of other companies. Mr. Andersen holds a Master of Business and Economics from BI Norwegian Business School. Number of shares*: 0. Number of shares controlled by close associate: 62 318 296. Number of RSUs granted: 344 518.
John Andersen
Chairman of the Board
Ms. Berdal has been a self-employed corporate adviser, lecturer, and investor since 2005. She is the Chair of the Board of Directors of Goodtech ASA and Connect Bus AS, and she sits on the Boards of Freyr Ltd., Electromagnetic Geoservices ASA, Energima AS, KLP Eiendom AS, Norsk Titanium AS, Kongsberg Digital Holding ASA, and the Norwegian branch of Transparency International, and also serves as the chair of the Nomination Committee of Borregaard ASA. Ms. Berdal holds a Master of Laws from the University of Oslo and was previously a partner at the law firm Arntzen de Besche in Oslo and as in-house legal adviser to TOTAL Norge AS. Number of shares: 416 990. Number of RSUs granted: 344 518.
Mimi Berdal
Director of the Board
Mr. Schnelle is an independent interim management consultant and currently the interim Chief Financial Officer in the Topro Mobility group and has over a decade of management experience within multiple industries. He has previously held the position of Chief Financial Officer and Chief Executive Officer in Team Tankers International Ltd. and Chief Financial Officer in Nordic Mining ASA. He holds a Master of Science in Business and Economics from BI Norwegian Business School in Oslo, Norway. Mr. Schnelle is a Norwegian citizen and resides in Oslo, Norway.
Jens Gisle Schnelle
Director of the Board
Ms Gidner has 30 years in international management, with significant achievements in strategic development and sales growth, repeatedly building new Life Science businesses. Steep sales growth in global Pharma CDMO corporations took her to corporate executive roles in the USA and Germany for Cambrex Corp and Lanxess Corp. She built Pharma out-licencing internationally for Novozymes Biopharma, Denmark and managed a Clinical Trial Business Unit in Berlin, Germany. In recent years she has been holding CEO and Board positions in publicly listed Swedish Biotech companies including SelectImmune Pharma and Ziccum. Ms Gidner holds a Master of Science in Biotechnology from Swedish Lund Institute of Technology plus the French Elite University ENSIGC, as well as an MBA from Swedish Ekonomicentrum.
Ann Gidner
Director of the Board
Dr Thomas Ramdahl is a pharmaceutical executive with over 25 years of clinical and development experience. In 2001, he became President and the first CEO of Algeta ASA. When Dr Ramdahl joined Algeta, he was one of six employees and he played an instrumental role in its success, including the approval of the alpha particle emitting radiopharmaceutical Xofigo®, serving in several senior positions within the company through to and post the acquisition of Algeta by Bayer AG in 2014 for US$2.9 billion. Following the acquisition Thomas served as CEO of Bayer AS until 2018. Thomas currently serves on the boards of Precirix, Clarity Pharmaceuticals and Agiana Pharmaceuticals. Thomas has authored more than 40 publications and is a co-inventor of several patents. Thomas gained his PhD in environmental chemistry from the University of Oslo and holds a Master of Science in organic chemistry from the Norwegian Institute of Technology.
Thomas Ramdahl
Director of the Board
